Coosemans M H, Barutwanayo M, Onori E, Otoul C, Gryseels B, Wéry M
Projet de Lutte contre les Maladies transmissibles et carentielles, Bujumbura, Burundi.
Trans R Soc Trop Med Hyg. 1987;81(1):151-6. doi: 10.1016/0035-9203(87)90310-5.
In this study the efficacy of chlorproguanil (20 mg base weekly) was compared in schoolchildren with that of chloroquine (200 mg base weekly) and that of both drugs combined (20 mg base + 200 mg base weekly). The double blind trial was performed in the rice field area of the Ruzizi valley in Burundi, where Plasmodium falciparum is widely resistant to chloroquine, and where pyrimethamine resistance with cycloguanil cross-resistance had been demonstrated. After 17 weeks, when the trial was ended, 60% breakthroughs had been observed among the children taking chloroquine, 72% among those under chlorproguanil and 61% among those under chlorproguanil and chloroquine. In children weighing between 15 and 24 kg, the failure rate was significantly higher in those treated with chlorproguanil than in the group treated with chloroquine. No difference in efficacy was observed in children weighing 25 to 39 kg. There was no significant increase of efficacy when chlorproguanil was given in association with chloroquine. The mean titre of fluorescent antibodies was the same in each treated group on week 5 and week 15. The comparison of these data with the infection rates in non-protected children suggests that malaria could not be prevented with any of the drug regimens utilized in the study.
在本研究中,对在校儿童使用氯胍(碱基20毫克/周)的疗效与氯喹(碱基200毫克/周)以及两种药物联合使用(碱基20毫克 + 碱基200毫克/周)的疗效进行了比较。该双盲试验在布隆迪鲁齐齐河谷的稻田地区进行,那里恶性疟原虫对氯喹广泛耐药,并且已证实存在乙胺嘧啶与环氯胍交叉耐药的情况。17周后试验结束时,服用氯喹的儿童中观察到60%出现突破性感染,服用氯胍的儿童中这一比例为72%,服用氯胍和氯喹联合用药的儿童中为61%。在体重15至24千克的儿童中,接受氯胍治疗的儿童失败率显著高于接受氯喹治疗的组。在体重25至39千克的儿童中未观察到疗效差异。氯胍与氯喹联合使用时疗效没有显著提高。在第5周和第15周时,每个治疗组的荧光抗体平均滴度相同。将这些数据与未受保护儿童的感染率进行比较表明,该研究中使用的任何一种药物治疗方案都无法预防疟疾。